In core-binding factor (CBF) AML, the co-existing KIT proto-oncogene receptor tyrosine kinase (KIT) gene mutation is associated with worse outcome [6]; although, the ELN classification does not include KIT mutation because the negative effect can be negated if a three-log or deeper reduction in minimal residual disease is achieved after induction therapy [7]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.